Home HealthTopics Health Centers Reference Library Research
Join us on Facebook Join us on Facebook Share on Facebook
Print this pageEMail this page

Pharmacy and Medications

Mylotarg (gemtuzumab ozogamicin): Withdrawn from Market Due to Potential Safety Risks

  • ATTENTION: The drug gemtuzumab ozogamicin (sold as Mylotarg) was withdrawn from the US market on June 21, 2010 due to potential safety risks.
FDA RECOMMENDATION: If Mylotarg is part of your therapy,
    • Mylotarg will not be commercially available to new patients.
    • Patients who are currently receiving the drug may complete their therapy following consultation with their health care professional.
    • Health care professionals should inform all patients receiving Mylotarg of the product?s potential safety risks.
For additional information about this withdrawal, please follow the link below:

For more information:

Go to the Pharmacy and Medications health topic, where you can:

This article is a NetWellness exclusive.

Last Reviewed: Feb 04, 2011

David Baker, PharmD, DABAT
Formerly, Clinical Assistant Professor of Pharmacy
College of Medicine
The Ohio State University